Managing light chain deposition disease

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 183-184

  Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MELPHALAN;

DRUG MEGADOSE; FANCONI RENOTUBULAR SYNDROME; HUMAN; KIDNEY INJURY; LIGHT CHAIN DEPOSITION DISEASE; MULTIPLE MYELOMA; NOTE; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MULTIPLE MYELOMA; PYRAZINES;

EID: 84856088936     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.622423     Document Type: Note

References (13)

1. Minarik J, Scudla V, Tichy T, et al. Induction treatment of light chain deposition disease with bortezomib-rapid hematological response with persistence of renal involvement. Leuk Lymphoma 2011;53:330-331.
2. Gertz MA. Managing myeloma kidney. Ann Intern Med 2005;143: 835-837. (Pubitemid 41780422)
3. Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004;104:40-42. (Pubitemid 38879834)
4. Randall RE, Williamson WC, Jr., Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med 1976;60:293-299.
5. Preud'homme JL, Aucouturier P, Touchard G, et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46:965-972. (Pubitemid 24319932)
6. Hotta O, Taguma Y. Resolution of nodular glomerular lesions in a patient with light-chain nephropathy. Nephron 2002;91:504-505. (Pubitemid 34765254)
7. Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-343.
8. Telio D, Shepherd J, Forrest D, et al. High-dose melphalan followed by ASCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant 2011.
9. Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008;23:2052-2057. (Pubitemid 351768166)
10. Kaposztas Z, Kahan BD, Katz SM, et al. Bortezomib Successfully Reverses Early Recurrence of Light-Chain Deposition Disease in a Renal Allograft: A Case Report. Transplant Proc 2009;41:4407-4410.
11. Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009;94:300-302.
12. Short AK, O'Donoghue DJ, Riad HN, et al. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 2001;21:237-240. (Pubitemid 32620202)
13. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004;43:147-153. (Pubitemid 38049446)